Refine by
Clinical Testing Articles & Analysis
269 news found
A Unique Challenge and Opportunity for Higher Education Across the country, colleges and universities were forced to make difficult decisions about the Fall 2020 semester as a result of the ongoing COVID-19 pandemic. Rollins College was no exception. However, early in their planning, administrators saw a unique opportunity to preserve some of the traditional college experience by utilizing new, ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, announces the expansion of its medical device testing capabilities and introduces Balloon Catheter Testing Services for the development of safe and effective medical devices. ...
BySTEMart
A Centers for Disease Control and Prevention (CDC) report published on October 3, 2024, linked Burkholderia multivorans infections to ice machines in multiple healthcare facilities in the western United States. This post summarizes key findings, implications, and recommended practices for healthcare providers to ensure patient ...
“The capabilities that SOPHiA GENETICS provides, from assay development to clinical trial use, help enable this first-in-human precision medicine clinical ...
As part of a larger, strategic collaboration, the two companies are now expanding upon a pilot program that utilizes Next, Tempus’ care pathway intelligence platform, to help physicians determine if their patients with NSCLC may benefit from guideline-directed molecular testing, including testing for epidermal growth factor receptor (EGFR) mutations. ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. ...
ByTempus
These services allow manufacturers to test and refine their products prior to full-scale production, streamlining the development process of new medical devices and minimizing risk to save time and costs. ...
BySTEMart
In addition, PDMS is the most widely used material for the manufacture of microfluidic devices, which are an important technology for the development of systems for drug delivery, DNA sequencing, clinical diagnostics, point-of-care testing, and chemical synthesis. The materials used in these systems should be biocompatible, optically transparent, rapid to ...
Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. ...
ByCELLINK
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, in Washington. ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
The new site offers dedicated space for materials engineering, electrical engineering, additive manufacturing, data science research, and clinical testing of our DeepGluco™ product. Our site provides several major advantages that the team has been looking forward to, including power supply to run commercial grade 3D printers and other equipment needed for ...
ByAlertgy
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at ...
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer detection and monitoring of lung cancer. As ...
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure. ...
ByBayer AG
“This IP portfolio, including granted patents originally developed by Professor Robert Langer’s laboratory allows Suono Bio to build upon these insights to develop patient-ready treatments as we get set for clinical testing.” "The patents included in this license, along with several other patent applications filed by Suono Bio, are part of an ...
On the one hand, I participate in testing sessions with different types of users with different levels of injury, and report what works and what does not. ...
“Orgenesis, through its newly formed POCare services subsidiary, has commenced clinical grade production, in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid for the supply of clinical-grade batches of the cell-based product intended for intravenous administration. The nasal delivery of the cell-based product has only ...
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and ...